Taysha Gene Therapies 

Yahoo Finance • 21 days ago

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monoge... Full story

Yahoo Finance • last month

Is Taysha Gene Therapies Inc. (TSHA) One of the Must-Buy Penny Stocks to Buy Now?

Taysha Gene Therapies Inc. (NASDAQ:TSHA) is a must-buy penny stock to buy now. On November 13, Piper Sandler analyst Biren Amin reaffirmed his Buy rating on Taysha Gene Therapies, assigning a $9 price target. On November 5, Truist Financia... Full story

Yahoo Finance • 2 months ago

Taysha outlines accelerated BLA timeline for TSHA-102 with FDA Breakthrough Therapy designation and full global rights

Earnings Call Insights: Taysha Gene Therapies (TSHA) Q3 2025 MANAGEMENT VIEW * CEO Sean Nolan stated, “The recent regulatory clarity and progress we've achieved, which was enabled by the strength of our REVEAL Part A data set, rigorous... Full story

Yahoo Finance • 2 months ago

Taysha Gene Therapies regains full rights to TSHA-102

designer491/iStock via Getty Images * Taysha Gene Therapies (NASDAQ:TSHA [https://seekingalpha.com/symbol/TSHA]) has announced that it has regained complete rights to its leading program, TSHA-102, which is currently being evaluated for... Full story

Yahoo Finance • 2 months ago

Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome

The 2022 Option Agreement between Astellas and Taysha has expired Regaining full rights to TSHA-102 Rett syndrome program enables Taysha to focus on driving its long-term value with full strategic flexibility and optionality TSHA-102 has... Full story

Yahoo Finance • 3 months ago

Collegium Pharmaceutical, Inc. (COLL): A Bull Case Theory

We came across a bullish thesis on Collegium Pharmaceutical, Inc. on The Catholic Capitalist’s Substack by Logan Shearer. In this article, we will summarize the bulls’ thesis on COLL. Collegium Pharmaceutical, Inc.'s share was trading at $... Full story

Yahoo Finance • 3 months ago

Taysha soars on FDA breakthrough therapy status for lead asset

[FDA headquarters in Washington DC.] JHVEPhoto Taysha Gene Therapies (NASDAQ:TSHA [https://seekingalpha.com/symbol/TSHA]) jumped ~39% on Thursday after the U.S. FDA granted its Breakthrough Therapy designation for the company's lead candi... Full story

Yahoo Finance • 4 months ago

Earnings call transcript: Taysha Gene's Q2 2025 revenue beats forecast

Taysha Gene Therapies Inc. reported its financial results for the second quarter of 2025, revealing a notable revenue beat compared to forecasts. The company posted a revenue of $1.98 million, surpassing the expected $1.82 million, marking... Full story

Yahoo Finance • 4 months ago

Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Commenced site activation for REVEAL pivotal trial in accordance with previously aligned upon key design elements, following receipt of No Objection Letter (NOL) from Health Canada and feedback from the FDA; patient enrollment anticipated... Full story

Yahoo Finance • 5 months ago

Taysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12

DALLAS, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monoge... Full story

Yahoo Finance • 5 months ago

Cumberland Pharmaceuticals Leads The Charge With 2 Other Prominent Penny Stocks

As the U.S. stock market experiences fluctuations with major indices like the Dow Jones and S&P 500 retreating from early-session gains, investors are keenly observing economic indicators and trade developments. Amid these broader market d... Full story

Yahoo Finance • 6 months ago

BofA Securities initiates coverage on Taysha Gene Therapies stock with Buy rating

Investing.com - BofA Securities initiated coverage on Taysha Gene Therapies (NASDAQ:TSHA) with a Buy rating and a price target of $8.00 on Friday. The stock, currently trading at $2.55, has shown strong momentum with a 45% gain over the pa... Full story

Yahoo Finance • 6 months ago

Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory

We came across a bullish thesis on Sarepta Therapeutics, Inc. on Stock Region Research’s Substack by Stock Region. In this article, we will summarize the bulls’ thesis on SRPT. Sarepta Therapeutics, Inc.'s share was trading at $17.23 as of... Full story

Yahoo Finance • 6 months ago

Taysha Gene Therapies' SWOT analysis: promising Rett syndrome therapy boosts stock outlook

Taysha Gene Therapies, Inc. (NASDAQ:TSHA), with a market capitalization of $545 million, has emerged as a prominent player in the gene therapy space, focusing on developing treatments for central nervous system (CNS) disorders. The stock h... Full story

Yahoo Finance • 7 months ago

Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program

Recently disclosed clinical cohort data from high (1x1015 total vg) and low dose (5.7x1014 total vg) TSHA-102 from REVEAL adolescent/adult and pediatric Phase 1/2 trials Caregiver research regarding gain/regain of developmental milestones... Full story

Yahoo Finance • 7 months ago

Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

DALLAS, May 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogen... Full story

Yahoo Finance • 7 months ago

Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

DALLAS, May 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogen... Full story

Yahoo Finance • 7 months ago

Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of the REVEAL Adult/Adolescent and Pediatric Trials Evaluating TSHA-102

Natural history data analysis established patients ≥ six years of age are in developmental plateau, with a ~0% likelihood of gaining/regaining developmental milestones across the core functional domains of Rett syndrome Written alignment... Full story

Yahoo Finance • last year

Is Taysha Gene Therapies, Inc. (TSHA) the Best NASDAQ Stock Under $5?

We recently compiled a list of 7 Best NASDAQ Stocks Under $5. In this article, we will look at where Taysha Gene Therapies, Inc. (NASDAQ:TSHA) ranks among the best NASDAQ stocks under $5. Job Market Cools Yet Economists Remain Optimistic... Full story

Yahoo Finance • 2 years ago

Taysha Gene Therapies Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome Patients

Health Canada authorized the Company’s protocol amendment that expands eligibility to include patients aged 12 and older with stage four Rett syndrome in the REVEAL Phase 1/2 adult trial in Canada Protocol amendment broadens TSHA-102 trea... Full story